Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 2713-33-9 Chemical Structure| 2713-33-9

Structure of 2713-33-9

Chemical Structure| 2713-33-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Hwang, Dong-Jin ; Yang, Chuanhe ; Wang, Yinan ; Kelso, Hannah ; Pochampally, Satyanarayana ; Pfeffer, Lawrence M , et al.

Abstract: Background/Objectives: Human glioblastoma (GBM) is the most aggressive brain cancer in adults and a highly treatment-refractory malignancy. The overall prognosis for the GBM is extremely poor, with a median survival of 12–14 months after initial diagnosis. Many GBM patients initially respond to the DNA alkylating agent temozolomide (TMZ), but patients often become therapy-resistant, and tumors recur. We previously reported that treatment with PFI-3, which is a small molecule inhibitor of the bromodomain of the BRG1 subunit of the SW1/SNF chromatin remodeling complex, enhanced the sensitivity of GBM cells to TMZ in vitro and in vivo GBM animal models. Our general objective was to perform an SAR study of new diphenyl PFI-3 analogs. Methods: New structural analogs of PFI-3 were developed, synthesized, and tested for their ability to enhance TMZ-induced GBM cell death by ELISA. Results: Following on the enhanced activity of compounds 2a and 2b, new diphenyl PFI-3 analogs with specific structural adjustments were made to better understand the structural requirements to optimize function. Additionally, several new structurally different candidates (e.g., 4a, 4b, and 5) showed much better efficacy in sensitizing GBM cells to TMZ-induced GBM cell death. Conclusions: Four series of PFI-3 analogs (2, 3, 4, and 5) were designed, synthesized, and tested for the ability to sensitize GBM cells to TMZ-induced cell death. Series 2 optimized the A-ring and R-isomer chirality. Series 3 used a 5-membered linker with weak activity. Series 4’s di-phenyl urea compounds showed better bromodomain inhibition. Series 5’s methoxyphenyl-B-ring analogs were exceptionally strong inhibitors.

Keywords: bromodomain ; glioblastoma (GBM) ; therapeutic enhancing drug (TED) ; anti-GBM activity ; structure-activity relationship (SAR) ; PFI-3 analog ; temozolomide (TMZ)

Purchased from AmBeed: ; ; ;

Alternative Products

Product Details of [ 2713-33-9 ]

CAS No. :2713-33-9
Formula : C6H4F2O
M.W : 130.09
SMILES Code : OC1=CC=C(F)C(F)=C1
MDL No. :MFCD00010315
InChI Key :BNPWVUJOPCGHIK-UHFFFAOYSA-N
Pubchem ID :75927

Safety of [ 2713-33-9 ]

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H228-H302+H312-H314
Precautionary Statements:P210-P280-P305+P351+P338-P310
Class:8(4.1)
UN#:2921
Packing Group:

Computational Chemistry of [ 2713-33-9 ] Show Less

Physicochemical Properties

Num. heavy atoms 9
Num. arom. heavy atoms 6
Fraction Csp3 0.0
Num. rotatable bonds 0
Num. H-bond acceptors 3.0
Num. H-bond donors 1.0
Molar Refractivity 28.38
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

20.23 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.39
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.06
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.51
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

2.34
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.23
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.11

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.44
Solubility 0.475 mg/ml ; 0.00365 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.11
Solubility 1.0 mg/ml ; 0.0077 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.34
Solubility 0.591 mg/ml ; 0.00454 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.63 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.06

Application In Synthesis of [ 2713-33-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 2713-33-9 ]

[ 2713-33-9 ] Synthesis Path-Downstream   1~4

  • 1
  • [ 2713-33-9 ]
  • [ 117902-15-5 ]
  • 2
  • [ 2713-33-9 ]
  • [ 17701-61-0 ]
  • C18H18F2O3 [ No CAS ]
YieldReaction ConditionsOperation in experiment
83% With potassium carbonate; potassium iodide; In N,N-dimethyl-formamide; at 130℃; for 2.5h; Take compound XIII-2 (833mg, 3.07mmol) and dissolve it in N, N-dimethylformamide (8mL, 0.38M).2,4-difluorophenol (624 mg, 4.8 mmol) was added sequentially,Potassium carbonate (829mg, 6mmol),Potassium iodide (132mg, 0.8mmol),The temperature was raised to 130 C.After 2.5 hours of reaction,TLC monitors the end of the reaction.Reduce the reaction solution to room temperature.Add water (80mL),Ethyl acetate extraction (10mL x 5),Combined organic phases,Wash with saturated brine (20mL x 2),Dry over anhydrous sodium sulfate.The solvent was distilled off under reduced pressure,The residue was purified by column chromatography (eluent: petroleum ether / ethyl acetate = 50/1),Compound XIII-3 was obtained (yellow oil, 818 mg, yield 83%).
  • 3
  • [ 2713-33-9 ]
  • [ 158690-56-3 ]
  • C13H17F2NO3 [ No CAS ]
  • 4
  • [ 2713-33-9 ]
  • [ 109431-87-0 ]
  • tert-butyl (3S)-3-(3,4-difluorophenoxy)pyrrolidine-1-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
70% With di-isopropyl azodicarboxylate; triphenylphosphine; In tetrahydrofuran; at 60℃; for 48h; To an ice-cooled solution of 3,4-difluorophenol (0.250 g, 1.92 mmol), tert-butyl (3R)-3- hydroxypyrrolidine-1-carboxylate (359 mg, 1.92 mmol) and triphenylphosphine (553 mg, 2.11 mmol) in tetrahydrofuran (4.80 mL) at 25 C was added diisopropyl azodicarboxylate (414 µL, 2.11 mmol) dropwise. The reaction mixture was stirred at 60 C for 48 h, then concentrated under reduced pressure. The crude oil was diluted with diethyl ether (10 mL) and then 1 M aqueous sodium hydroxide (10 mL) was added. The aqueous layer was extracted with diethyl ether (10 mL x 2). The combined organic layers were dried over magnesium sulfate, filtered and concentrated in vacuo. The crude material was purified via column chromatography (ISCO, 24 g silica gel, 0-20% ethyl acetate in hexanes over 20 min gradient) to give tert-butyl (3S)-3-(3,4-difluorophenoxy)pyrrolidine-1-carboxylate (400 mg, 1.33 mmol, 70%) as a yellow solid.1H NMR (300 MHz, Chloroform-d) d 7.08 (dt, J = 10.2, 9.1 Hz, 1H), 6.71 (ddd, J = 11.9, 6.6, 3.0 Hz, 1H), 6.58 (dtd, J = 9.2, 3.2, 1.8 Hz, 1H), 4.80 (dq, J = 6.1, 2.5 Hz, 1H), 3.68- 3.41 (m, 4H), 2.12 (dtd, J = 18.1, 13.4, 9.8 Hz, 2H), 1.48 (s, 9H).
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 2713-33-9 ]

Fluorinated Building Blocks

Chemical Structure| 147300-08-1

A109497 [147300-08-1]

4,5-Difluorobenzene-1,2-diol

Similarity: 0.94

Chemical Structure| 371-41-5

A267007 [371-41-5]

4-Fluorophenol

Similarity: 0.91

Chemical Structure| 75996-29-1

A137574 [75996-29-1]

5-Fluorobenzene-1,3-diol

Similarity: 0.89

Chemical Structure| 2713-34-0

A261289 [2713-34-0]

3,5-Difluorophenol

Similarity: 0.89

Chemical Structure| 372-20-3

A185840 [372-20-3]

3-Fluorophenol

Similarity: 0.88

Aryls

Chemical Structure| 147300-08-1

A109497 [147300-08-1]

4,5-Difluorobenzene-1,2-diol

Similarity: 0.94

Chemical Structure| 371-41-5

A267007 [371-41-5]

4-Fluorophenol

Similarity: 0.91

Chemical Structure| 75996-29-1

A137574 [75996-29-1]

5-Fluorobenzene-1,3-diol

Similarity: 0.89

Chemical Structure| 2713-34-0

A261289 [2713-34-0]

3,5-Difluorophenol

Similarity: 0.89

Chemical Structure| 372-20-3

A185840 [372-20-3]

3-Fluorophenol

Similarity: 0.88